This systematic mapping of 47 neurological cannabinoid trials provides clinicians with the first comprehensive view of where evidence exists and where it remains absent in neurology. The identification of persistent evidence gaps matters because it helps clinicians distinguish between conditions with meaningful research support versus those where cannabis recommendations remain largely empirical.
A systematic survey identified 47 clinical trials investigating cannabinoids for neurological conditions, revealing concentrated research in epilepsy and multiple sclerosis while exposing significant evidence gaps in common neurological presentations like headache, neuropathy, and movement disorders. The analysis demonstrates that despite growing clinical interest, rigorous trial data remains limited to a narrow subset of neurological applications. Most trials focused on CBD and THC formulations, with few investigating minor cannabinoids or specific dosing protocols for neurological symptoms.
“This survey confirms what we see clinically—patients ask about cannabis for dozens of neurological conditions, but we have quality evidence for maybe half a dozen. The gap between patient interest and research reality means neurologists need to be especially careful about distinguishing evidence-based recommendations from clinical intuition.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
FAQ
What is the clinical relevance rating of this cannabis research?
This research has been assigned a “High Clinical Relevance” rating (#80) by CED Clinical. This indicates the study provides strong evidence or policy relevance with direct clinical implications for patient care.
What medical condition does this cannabis study focus on?
Based on the categorization tags, this study focuses on epilepsy within the neurology field. The research appears to examine cannabis-based treatments for neurological seizure disorders.
What type of research methodology was used in this study?
This appears to be a clinical trial, as indicated by the “Clinical Trials” tag. The study follows evidence-based medicine principles to evaluate cannabis treatments in a controlled clinical setting.
Is this research newly published or recently updated?
Yes, this article is marked as “New” content. This suggests the research findings or clinical data have been recently published or made available to the medical community.
What makes this cannabis research clinically significant?
The high clinical relevance rating suggests this study provides actionable evidence that can directly inform clinical decision-making. The combination of rigorous clinical trial methodology and focus on epilepsy treatment makes it particularly valuable for neurologists and healthcare providers.